Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Canbridge Pharmaceuticals Inc.
Headquarters: Beijing, China
Website: http://www.canbridgepharma.com...
Year Founded: 2012
Status: Public
Industry Sector: HealthTechnology
CEO: James Xue, PhD, MBA
Number Of Employees: 67
Enterprise Value: $24,448,161
PE Ratio: -0.12
Exchange/Ticker 1: HKEX:1228
Exchange/Ticker 2: N/A
Latest Market Cap: $7,108,872
BioCentury | Nov 20, 2024
Discovery & Translation
Science Spotlight: A new obesity target may avoid nausea, muscle loss
BioCentury’s roundup of translational innovation: Embark/Novo discover new obesity target, Canbridge delivers large DMD gene, and more
BioCentury | Jun 2, 2023
Product Development
June 2 Quick Takes: Kisqali cuts recurrence risk in broad breast cancer population
Plus: BioNTech, OncoC4 build case for CTLA-4 product with lung cancer readout, and updates from Takeda, Poseida, Canbridge and more
BioCentury | Oct 5, 2022
Deals
LogicBio takeout brings new skills, platform to Alexion
AZ unit finds entry point to gene therapy in $68M acquisition
BioCentury | Jul 5, 2022
Management Tracks
Health Secretary Javid among ministers quitting U.K. government
Plus Hering made permanent CEO at Adagio and updates from Canbridge, Catalent, Nanoscope, and more
BioCentury | May 13, 2022
Management Tracks
New CEOs at CorMedix, Medigene
Plus updates from Elicio, Rejuvenate, Canbridge and more
BioCentury | Dec 11, 2021
Product Development
Dec. 10 Quick Takes: UCB’s rozanolixizumab meets in Phase III
Plus: Vifor-Angion product misses and updates from Arvinas-Pfizer, Canbridge, Totus and more
BioCentury | Apr 28, 2021
Product Development
April 27 Quick Takes: Merck, Gilead move to expand access to COVID-19 antivirals; plus Exscientia-Softbank, Lilly, Aldeyra, LogicBio, Canbridge, Daiichi, Ultivue, Provention
Initiatives by Merck & Co. Inc. (NYSE:MRK) and Gilead Sciences Inc. (NASDAQ:GILD) will expand availability of the companies’ antivirals in India as the country’s COVID-19 crisis
BioCentury | Mar 16, 2021
Deals
March 15 Quick Takes: Canada’s CPP leads insitro’s $400M series C; plus Bicara, Aveo, Gilead-Merck and more
Insitro Inc. said existing investor Canada Pension Plan Investment Board led its new $400 million series C round, which builds on a $143 million series B closed in May 2020. Also backing the
BioCentury | Feb 2, 2021
Management Tracks
Merck vet Drouet joining CRISPR; plus updates from Cerevance, Rinri, MOMA, Vivoryon, Kadimastem
Gene editing play CRISPR Therapeutics AG (NASDAQ:CRSP) hired Philippe Drouet as chief commercial officer. He was SVP, global oncology marketing & market access at Merck & Co. Inc. (NYSE:MRK),
Items per page:
1 - 10 of 38